PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while TRAW shows 25.00% growth. Joel Greenblatt would examine competitive advantage.
4.31%
Positive growth while TRAW shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth above 1.5x TRAW's 0.16%. Michael Burry would check for spending discipline.
-40.17%
G&A reduction while TRAW shows 21.48% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while TRAW shows 10.26% growth. Joel Greenblatt would examine advantage.
-8.25%
Total costs reduction while TRAW shows 10.26% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
D&A reduction while TRAW shows 25.00% growth. Joel Greenblatt would examine efficiency.
8.31%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
12.55%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth 1.25-1.5x TRAW's 137.76%. Martin Whitman would scrutinize strategy.
12.55%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth while TRAW declines. John Neff would investigate advantages.
15.52%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
3.21%
Share count reduction below 50% of TRAW's 0.11%. Michael Burry would check for concerns.
3.21%
Diluted share reduction below 50% of TRAW's 0.11%. Michael Burry would check for concerns.